celecoxib,ipilimumab,nivolumab,dostarlimab
bms,gsk
['niche']
 i ve had several instances of non-operative or watch-&amp;-wait approach in patients with msi tumors who have a response to immunotherapy. with the niche &amp; other neoadjuvant studies like leading the way, it s a huge opportunity/platform to build off of. #asco22 
Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22